Aktis Oncology, Inc. (AKTS) · Insider trading
What Aktis Oncology's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$114.31M
6 insiders, 9 trades
Sold, 12 months
$3.23M
3 insiders, 8% under a plan
Net, 12 months
+$111.08M
bought less sold
Latest filing
2026-09-24
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Nodelman OlegDirector | $40.00M | – | 2 | 2026-01-12 | – |
| Gadicke Ansbert10% owner | $20.03M | – | 1 | 2026-01-12 | – |
| Evnin Luke10% owner | $20.03M | – | 1 | 2026-01-12 | – |
| Kim Helen SusanDirector, 10% owner | $15.03M | – | 2 | 2026-01-12 | – |
| Vida Ventures II, LLC10% owner | $15.03M | – | 2 | 2026-01-12 | – |
| Foley ToddDirector, 10% owner | $4.19M | – | 1 | 2026-01-12 | – |
| Czibere AkosChief Medical Officer | – | $1.65M | 5 | 2026-09-23 | 7,401 |
| Ron-Bigger ShulamitChief Operating Officer | – | $1.39M | 3 | 2026-07-08 | 34,200 |
| Herrmann KenDirector | – | $196,532 | 3 | 2026-07-20 | 1,350 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Czibere AkosChief Medical Officer | Saleplan | 5,099 | 20.19 | $102,949 | 7,401 | Form 4 |
| 2026-09-23 | Czibere AkosChief Medical Officer | Saleplan | 7,401 | 21.03 | $155,643 | 0 | Form 4 |
| 2026-07-20 | Herrmann KenDirector | Sale | 3,506 | 24.56 | $86,107 | 1,350 | Form 4 |
| 2026-07-20 | Herrmann KenDirector | Sale | 1,350 | 24.56 | $33,156 | 0 | Form 4 |
| 2026-07-17 | Herrmann KenDirector | Sale | 3,065 | 25.21 | $77,269 | 0 | Form 4 |
| 2026-07-08 | Czibere AkosChief Medical Officer | Sale | 14,800 | 27.13 | $401,524 | 35,200 | Form 4 |
| 2026-07-08 | Czibere AkosChief Medical Officer | Sale | 30,829 | 27.95 | $861,671 | 4,371 | Form 4 |
| 2026-07-08 | Czibere AkosChief Medical Officer | Sale | 4,371 | 28.71 | $125,491 | 0 | Form 4 |
| 2026-07-08 | Ron-Bigger ShulamitChief Operating Officer | Sale | 15,800 | 27.13 | $428,654 | 34,200 | Form 4 |
| 2026-07-08 | Ron-Bigger ShulamitChief Operating Officer | Sale | 30,000 | 27.94 | $838,200 | 4,200 | Form 4 |
| 2026-07-08 | Ron-Bigger ShulamitChief Operating Officer | Sale | 4,200 | 28.75 | $120,750 | 0 | Form 4 |
| 2026-01-12 | Gadicke Ansbert10% ownerwith Mpm Asset Management LLC, Oncology Impact Private Investment Fund 2, L.P. | Buyindirect | 1,112,777 | 18.00 | $20.03M | 10,260,064 | Form 4 |
| 2026-01-12 | Evnin Luke10% ownerwith Mpm Oncology Innovations Fund LP, Mpm Bioventures 2018 (b), L.P., Mpm Bioventures 2018, L.P., Mpm Asset Management Investors Bv2018 LLC, Mpm BioVentures 2018 GP LLC, Mpm BioVentures 2018 LLC, Mpm Oncology Innovations Fund GP LLC | Buyindirect | 1,112,777 | 18.00 | $20.03M | 10,260,064 | Form 4 |
| 2026-01-12 | Foley ToddDirector, 10% owner | Buyindirect | 232,870 | 18.00 | $4.19M | 4,235,403 | Form 4 |
| 2026-01-12 | Nodelman OlegDirectorwith EcoR1 Capital, LLC | Buyindirect | 2,077,779 | 18.00 | $37.40M | 4,348,658 | Form 4 |
| 2026-01-12 | Nodelman OlegDirectorwith EcoR1 Capital, LLC | Buyindirect | 144,443 | 18.00 | $2.60M | 347,305 | Form 4 |
| 2026-01-12 | Kim Helen SusanDirector, 10% owner | Buyindirect | 812,455 | 18.00 | $14.62M | 5,671,825 | Form 4 |
| 2026-01-12 | Kim Helen SusanDirector, 10% owner | Buyindirect | 22,545 | 18.00 | $405,810 | 157,387 | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC10% ownerwith Vida Ventures Ii-a, LLC | Buyindirect | 812,455 | 18.00 | $14.62M | 5,671,825 | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC10% ownerwith Vida Ventures Ii-a, LLC | Buyindirect | 22,545 | 18.00 | $405,810 | 157,387 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
17 × conversion6 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-23 | Czibere AkosChief Medical Officer | Option exercise M | +12,500 | 4.95 | 12,500 | Form 4 |
| 2026-07-20 | Herrmann KenDirector | Option exercise M | +3,506 | 0.08 | 3,506 | Form 4 |
| 2026-07-20 | Herrmann KenDirector | Option exercise M | +1,350 | 1.91 | 4,856 | Form 4 |
| 2026-07-17 | Herrmann KenDirector | Option exercise M | +3,065 | 0.08 | 3,065 | Form 4 |
| 2026-07-08 | Czibere AkosChief Medical Officer | Option exercise M | +50,000 | 4.95 | 50,000 | Form 4 |
| 2026-07-08 | Ron-Bigger ShulamitChief Operating Officer | Option exercise M | +50,000 | 3.66 | 50,000 | Form 4 |
| 2026-01-12 | Gadicke Ansbert10% owner | Conversion C | +1,314,262 | – | 1,655,971 | Form 4 |
| 2026-01-12 | Gadicke Ansbert10% owner | Conversion C | +5,914,197 | – | 7,570,168 | Form 4 |
| 2026-01-12 | Gadicke Ansbert10% owner | Conversion C | +1,577,119 | – | 9,147,287 | Form 4 |
| 2026-01-12 | Evnin Luke10% owner | Conversion C | +1,314,262 | – | 1,655,971 | Form 4 |
| 2026-01-12 | Evnin Luke10% owner | Conversion C | +5,914,197 | – | 7,570,168 | Form 4 |
| 2026-01-12 | Evnin Luke10% owner | Conversion C | +1,577,119 | – | 9,147,287 | Form 4 |
| 2026-01-12 | Foley ToddDirector, 10% owner | Conversion C | +597,391 | – | 597,391 | Form 4 |
| 2026-01-12 | Foley ToddDirector, 10% owner | Conversion C | +2,688,270 | – | 3,285,661 | Form 4 |
| 2026-01-12 | Foley ToddDirector, 10% owner | Conversion C | +716,872 | – | 4,002,533 | Form 4 |
| 2026-01-12 | Nodelman OlegDirector | Conversion C | +2,270,879 | – | 2,270,879 | Form 4 |
| 2026-01-12 | Nodelman OlegDirector | Conversion C | +202,862 | – | 202,862 | Form 4 |
| 2026-01-12 | Nodelman OlegDirector | Conversion C | +128,506 | – | 128,506 | Form 4 |
| 2026-01-12 | Kim Helen SusanDirector, 10% owner | Conversion C | +4,859,370 | – | 4,859,370 | Form 4 |
| 2026-01-12 | Kim Helen SusanDirector, 10% owner | Conversion C | +134,842 | – | 134,842 | Form 4 |
| 2026-01-12 | Segal Lloyd MitchellDirector | Conversion C | +19,631 | – | 19,631 | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC10% owner | Conversion C | +4,859,370 | – | 4,859,370 | Form 4 |
| 2026-01-12 | Vida Ventures II, LLC10% owner | Conversion C | +134,842 | – | 134,842 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.